Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of epcoritamab + lenalidomide versus rituximab + gemcitabine + oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma
CTR20244540Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epcoritamab, lenalidomide, rituximab, gemcitabine and oxaliplatin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Progression-free survival. Started Jan 2025; status: active.
02
Drugs
epcoritamablenalidomiderituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20244540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244540.